Regenerative medicine firm Orthocell has obtained CE-Mark for its CelGro medical device, allowing marketing within the European Union (EU) countries.

Developed using the firm’s SMRT tissue engineering process, the collagen scaffold device is indicated for use in various dental bone and soft tissue regeneration procedures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CelGro is designed to target a range of orthopaedic, reconstructive and surgical applications with global commercial potential in current addressable bone, tendon, nerve and cartilage markets.

Orthocell managing director Paul Anderson said: “European regulatory approval for CelGro marks a major milestone for Orthocell as it enables commercial roll-out in the lucrative dental bone and soft tissue regeneration market, where there is a significant and growing demand and market opportunity.

“The CE-Mark also validates the potential of the entire technology platform by endorsing CelGro’s clinical performance and quality manufacturing.”

“The approval is expected to support the device’s dental regulatory applications in other key markets, including the US, Japan and Australia.”

The approval is expected to support the device’s dental regulatory applications in other key markets, including the US, Japan and Australia.

Orthocell is currently working on forming strategic commercial partnerships for product distribution in Europe and other select regions.

In addition to dental and tissue regeneration, the CelGro technology platform could be used in different neurological, orthopaedic and surgical applications such as peripheral nerve repair, tendon, ligaments, cartilage and bone, general surgery, and urogynaecological procedures.

During clinical studies, the device is reported to have demonstrated improved tissue-ingrowth and repair when used for rotator cuff tendon repair in the shoulder, bone regeneration in the jaw and re-joining of severed or damaged peripheral nerves.